GEMVAX 'GV1001' Showcased as an Outstanding Achievement in Dementia Overcoming R&D Project

GemVax & Kael (GemVax)'s Alzheimer's disease treatment 'GV1001' global clinical trial will be introduced as an excellent achievement project of the Dementia Overcoming Research and Development Project.

[Photo by Jembex]

GemVax announced on the 26th that it will present the status of Phase 2 clinical trials of the new Alzheimer's disease treatment GV1001 using peptides in the United States and seven European countries at the 'Dementia Overcoming Research and Development Project Phase 1 ('20~'22) Excellent Achievement Sharing Meeting' held at The Plaza Hotel in Seoul on the 27th.

The Dementia Overcoming Research and Development Project is a joint initiative by the Ministry of Science and ICT and the Ministry of Health and Welfare to support comprehensive research and development (R&D) covering dementia prevention, diagnosis, and treatment. The global clinical trial of GV1001 was finally selected as a supported project by the project team in 2020.

At the event, among the 65 supported projects selected in Phase 1 of the Dementia Overcoming Research and Development Project, a total of seven projects, including GemVax, will be introduced as excellent achievements.

A GemVax official stated, “During the project team support period, Investigational New Drug (IND) approvals for clinical trials in the United States and seven European countries were all completed, and the clinical trials have started with participant enrollment, achieving significant progress.” He added, “We will devote ourselves to proving the therapeutic effect of GV1001 on Alzheimer's disease and do our best to contribute to reducing the socioeconomic burden on the nation caused by dementia.”

This content was produced with the assistance of AI translation services.